Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in…

Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodríguez Á. JAMA 2022

Document identifier
CEI-BR-013
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodríguez Á
Title
Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial
Source
JAMA
Year
2022
Volume, issue, pages
327(6):534–545
Digital object identifier
10.1001/jama.2022.0078
PubMed identifier
35133415
Record type
Journal article
Institute identifier
CEI-BR-013

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

DocumentSeries
Monograph: TirzepatideCompound monograph
1 citing document.

§1.3Subject tags

tirzepatide insulin SURPASS

Compound Evidence Institute · CEI-BR-013 · https://compoundevidence.com/bibliography/dahl2022/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.